Findings show promise following diagnosis of impaired fasting glucose<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Feb. 14, 2022 (HealthDay News) — A model using routine clinical information can predict pancreatic ductal adenocarcinoma (PDA) following diagnosis of impaired fasting glucose (IFG), according to a study published in the January issue of the European Journal of Gastroenterology & Hepatology<\/em>.<\/p>\n Ben Boursi, M.D., from the Sheba Medical Center in Ramat Gan, Israel, and colleagues developed and internally validated a new model to predict PDA risk among those newly diagnosed with IFG. The analysis included 138,232 eligible patients with an initial IFG diagnosis (1995 to 2013).<\/p>\n The researchers found that during the study period, 0.2 percent of individuals were diagnosed with PDA within three years, with a median time from IFG diagnosis to clinical PDA diagnosis of 326 days. Age, body mass index, proton pump inhibitor use, total cholesterol, low-density lipoprotein cholesterol, alanine aminotransferase, and alkaline phosphatase were included in the final prediction model. The model showed good discrimination and calibration.<\/p>\n “Over the last few years our team has been aiming to build a model whereby people at risk of developing pancreatic cancer could be flagged at as early a stage as possible allowing curative resection of the disease,” Boursi said in a statement. “If our models are validated in a prospective study, this finding could extend our ability to detect pancreatic ductal adenocarcinomas at an earlier stage and improve health outcomes.”<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n